Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 356 participants.
Also called NCT06932874
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 356 participants
- Registry
-
NCT06932874
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06932874. Randomized; no masking; primary purpose treatment. Start 2025-03-04 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease
- Condition
- Atherosclerotic Heart Disease
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Glucophage (Metformin Hydrochloride Tablets)
- Intervention (Drug)
- New sustained-release metformin tablets (Ⅲ)
- Lead sponsor
- China National Center for Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct06932874- Content hash
cb17a55c8e623f646d3309cc6a713271a3ebe90a821c82e28d19215cd00c03e7